This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
marijuana: Archive
Should You Buy TLRY Stock After Encouraging Q1 Results?
by Sundeep Ganoria
Tilray's return to profitability, stronger cash flow, and expanding global cannabis and beverage operations highlight its renewed growth story.
marijuana medical
Should You Buy or Sell CURLF Stock Amid Renewed Legalization Hopes?
by Sundeep Ganoria
Curaleaf's shares have soared over 200% on renewed legalization optimism, but domestic weakness and profit hurdles cloud the outlook.
marijuana medical
From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects
by Aparajita Dutta
Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism.
marijuana
Trump's CBD Video Sparks Buzz: 3 Cannabis Stocks to Watch
by Sundeep Ganoria
Trump's CBD video fuels momentum in cannabis, with Village Farms, Canopy Growth, and Tilray emerging as stocks to watch in 2025.
marijuana medical
Here's Why JAZZ Stock Is an Unconventional Cannabis Investment
by Sundeep Ganoria
Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.
biotechs marijuana medical
Green Thumb Launches $50M Buyback: Time to Get Bullish on the Stock?
by Sundeep Ganoria
GTBIF launches a $50 million share buyback program, signaling confidence in long-term growth despite market and pricing pressures.
marijuana medical
Cannabis Stock CRLBF Gains 25% in a Month: Time to Buy, Sell or Hold?
by Sundeep Ganoria
CRLBF surges 25% this month on reform hopes, but revenue declines, margin pressure and stiff competition cloud its outlook.
marijuana
Cannabis Stock CRON Trades Near 52-Week High: How to Play
by Sundeep Ganoria
Cronos trades near its 52-week high as international growth boosts sales, but losses and stiff competition weigh on its outlook.
marijuana medical
Cannabis Stock VRNOF Soars 178% in a Month: Time to Buy, Sell or Hold?
by Sundeep Ganoria
Verano's stock has surged 178% in a month on reform hopes, but pricing pressure and stiff competition test its momentum.
marijuana medical
3 Cannabis Stocks to Watch After Trump's Marijuana Rescheduling Signal
by Sundeep Ganoria
Trump's marijuana rescheduling remarks reignite cannabis optimism, putting Village Farms, Canopy Growth and High Tide in focus.
marijuana medical pot-stocks